Real-World Insights on Voclosporin for Lupus Nephritis

Real-World Insights on Voclosporin for Lupus Nephritis

The clinical study NCT05337124 is a U.S.-based observational registry evaluating how voclosporin (Lupkynis®) is used in real-world clinical practice for patients with lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Study Overview

• Type: Observational (non-interventional registry)
• Population: Adults (18+) with biopsy-confirmed lupus nephritis
• Focus: Patients receiving or starting voclosporin as part of standard care
• Goal: Assess real-world effectiveness, safety, and treatment patterns

Unlike traditional clinical trials, this study does not assign treatments. Instead, it collects ongoing data from routine clinical practice to better understand how the drug performs outside controlled trial settings.

Why This Study Matters

Clinical trials have already shown that voclosporin can reduce proteinuria and help stabilize kidney function. This registry builds on that by answering an important question:
- Does it work as well in everyday patients as it does in controlled trials?

Key Early Findings

Preliminary real-world data suggest:

• Significant reduction in proteinuria within the first months of treatment
• Stable kidney function (eGFR) over time
• No new safety concerns, consistent with prior trials

The patient population also reflects real-world diversity, including substantial representation of Black and Hispanic patients—groups often underrepresented in clinical trials.

Bigger Picture

This study supports a growing shift toward triple immunosuppressive therapy (including voclosporin) as a frontline option for lupus nephritis.

By capturing real-world outcomes, the registry helps clinicians, researchers, and policymakers better understand how this treatment performs across diverse patient populations and everyday clinical settings.

Learn More: https://clinicaltrials.gov/study/NCT05337124